Biogen's Q4 Non-GAAP Earnings, Revenue Rise; 2025 Outlook Set

MT Newswires Live
12 Feb

Biogen (BIIB) reported Q4 non-GAAP earnings Wednesday of $3.44 per diluted share, up from $2.95 a year earlier.

Analysts polled by FactSet expected $3.35.

Revenue for the quarter ended Dec. 31 was $2.46 billion, up from $2.39 billion a year earlier.

Analysts surveyed by FactSet expected $2.41 billion.

The company said it expects fiscal 2025 non-GAAP EPS to fall in the range of $15.25 to $16.25.

Analysts polled by FactSet expect $16.33.

Biogen also said it expects fiscal 2025 revenue to decline by a mid-single-digit percentage year over year.

Analysts surveyed by FactSet expect revenue of $9.40 billion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10